



# Kit Protocol

Product Code: **ZHA-4000**

From Vasculogenesis to Angiogenesis

## **NOTE:**

**The cells in this kit require immediate attention**  
**Take care to follow the protocol instructions carefully**

### **Kit Contents**

#### *In this box:*

- 24 well tissue culture plate
- 96 well microtitre plate (for optional ELISA staining)
- 25ml Optimised Seeding Medium
- 125ml Optimised Growth Medium

#### *Shipped separately:*

- Ampoule of cryopreserved V2a Cells
- Seeding Medium Supplement
- Growth Medium Supplement
- Angiogenesis Control compounds (VEGF and Suramin)
- Mouse anti-human CD31 Primary Antibody
- Goat anti-mouse IgG Alkaline Phosphatase Secondary Antibody
- p-NPP and BCIP/NBT Substrate and Buffer Tablets

**For research use only**  
**Not for diagnostic or therapeutic use**

## Contents

1. Introduction
2. V2a Kit Format
3. Storage Temperature for Kit Components
4. Additional Equipment and Reagents Required
5. V2a Kit Protocol Summary
6. Guidelines for Test Material Preparation
7. General Tips
8. V2a Kit Protocol
9. Fixing and Staining Protocols
10. Scoring Results
11. Troubleshooting
12. Angiogenesis Related Products
13. References
14. Technical Assistance

Appendix I - Suggested protocol for containing contamination

**Please read the entire protocol before opening the kit or proceeding with an experiment.**

## 1. Introduction

Angiogenesis is the multistep process whereby new blood vessels develop from pre-existing vasculature. Angiogenesis plays a key role in numerous physiological and pathological processes including wound healing and the development of collateral circulation following an ischaemic episode<sup>1</sup>, reproduction-associated neovascularisation<sup>2</sup>, growth of solid tumours<sup>3</sup> and diabetic retinopathy<sup>4</sup>. Understanding the mechanism of angiogenesis will therefore provide new approaches to the treatment of a wide range of pathologies.

Angiogenesis is a complex process in which the following events are believed to play a critical role:

- Proteolytic degradation of the extracellular matrix<sup>5</sup>
- Directed migration of endothelial cells<sup>6,7</sup>
- Proliferation of endothelial cells<sup>8</sup>
- Deposition of new extracellular matrix<sup>5</sup>
- Formation of tubules and anastomosis of the newly formed vessels<sup>5,7</sup>

Experimental approaches to the study of these events have been limited by the lack of suitable models of angiogenesis. Several *in vivo* systems have been developed including the chick chorioallantoic membrane (CAM) assay<sup>9</sup> and the rabbit cornea model<sup>10</sup> but these systems are impractical for the study or screening of large numbers of samples and are far removed from angiogenesis in a human system. The *in vitro* methods currently in use have generally isolated the different component parts of the angiogenic process and have studied endothelial cell proliferation<sup>11</sup>, endothelial cell migration<sup>12</sup> or the ability of endothelial cells to associate into tubules when in contact with various matrix proteins<sup>13</sup>. None of these assay systems accurately reflect the angiogenic process in its entirety.

In the patented TCS Cellworks **V2a Kit**, human endothelial cells are co-cultured with other human cells in a specially designed medium. The endothelial cells initially form small islands within the culture matrix. They subsequently begin to proliferate and then enter a migratory phase during which they move through the matrix to form threadlike tubule structures. These gradually join up (by 1 - 2 weeks) to form a network of anastomosing tubules which closely resembles the capillary bed found in the CAM assay<sup>14-24</sup>. The tubules stain positive for von Willebrand's Factor, PECAM 1 and ICAM-2. They are also shown to secrete a matrix containing type IV collagen.

The **V2a Kit** assay is responsive to known micro and macro molecular inhibitors and stimulators of angiogenesis and so, unlike some other models, measures both positive and negative effects on angiogenesis. It yields reproducible dose response curves permitting comparison of different treatment regimes and product concentrations.

In addition to primary cells, seeding and growth media (with associated supplements), the **V2a Kit** also includes:

- Validated antibodies and reagents for tubule visualisation.
- Validated positive control (VEGF).
- Validated negative control (Suramin).

## 2. V2a Kit Format

The **V2a Kit** contains all of the cells and reagents necessary to successfully complete a 24 well angiogenesis assay. The kit contains a cryogenically preserved ampoule of matched cells, 24 well tissue culture plate, medium, supplements, control compounds and all staining reagents.

The **V2a Kit** is designed so that test compounds, conditioned media or tissue explants can be added to the culture at any time from the onset of vasculogenesis continuing through to advanced angiogenesis. The resulting effect on tubule formation can then be measured using TCS Cellworks Image analysis software, **AngioSys**.

Control wells that receive no treatment other than medium changes form extensive networks of branching tubules over a period of one to two weeks. This allows both angiogenic inhibitors and angiogenic stimulators to be assessed. The necessary medium changes are included in the kit.

Positive and negative control compounds are included in the **V2a Kit** which consist of validated concentrated stock solutions of VEGF (2ug/ml, positive control) and Suramin (1mM, negative control) ready to add to medium.

### BIOHAZARD NOTE

**The ZHA-4000 V2a Kit contains cells of human origin. Although the cells test negative for HIV-1, Hepatitis B, Hepatitis C, mycoplasma, bacteria and fungi, no test procedure can guarantee the absence of known and unknown infectious agents. Consequently, all products of human origin should always be considered potentially biohazardous and appropriate precautions should be taken. Use good laboratory practice and aseptic technique at all times.**

See for example Grizzle, W.E. and Potts, S.S. (1988) Guidelines to avoid personnel contamination by infectious agents in research laboratories, *J. Tissue Culture Methods* **11**; 4.

### 3. Storage Temperature for Kit Components:

24 well tissue culture plate	Room Temperature
96 well microtitre plate (for optional ELISA staining)	Room Temperature
25ml Optimised Seeding Medium	2 - 8°C
125ml Optimised Growth Medium	2 - 8°C
Anti-mouse IgG-AP Secondary Antibody	-20°C
Seeding Medium Supplement	-20°C
Growth Medium Supplement	-20°C
Suramin Control Compound (1mM)	-20°C
VEGF Control Compound (2ug/ml)	-20°C
Anti-human CD31 Primary Antibody	-20°C
p-NPP Substrate Tablet	-20°C
BCIP/NBT Substrate Tablet	-20°C
Tris BufferTablet	-20°C
Cryopreserved V2a Cells	-196°C

**Ensure kit contents are stored at the indicated temperatures immediately**

#### 4. Additional Equipment and Reagents Required

Class 2 laminar flow hood

Test materials to assay

Sterile serological pipettes

Automated pipette pump set to slow speed setting

Sterile containers for making up test compound dilutions

Sterile aspirating pipettes

Disposable syringe with 0.2µm filter disc

Micropipettes and pipette tips

Incubator set to 37°C with 5% CO<sub>2</sub> humidified atmosphere

70% ethanol

Dulbecco's Phosphate Buffered Saline

Bovine Serum Albumin (BSA)

3M NaOH and 96 well plate reader set to measure absorbance at 405nm (only required if performing ELISA with soluble p-NPP substrate)

Relevant personal protective equipment

## 5. V2a Protocol Summary

*Unpack kit and store reagents according to section 3*

### 5.1. Day 1

Prepare Optimised Seeding Medium and pre-equilibrate  
Add V2a Co-Culture Cells to Seeding Medium  
Add Cells and Medium to 24 well plate cell culture plate  
Incubate

### 5.2. Day 2

Prepare Optimised Growth Medium  
Dilute control and test compounds as required\*  
Pre-equilibrate Optimised Growth Medium and control/test dilutions  
Examine cultures microscopically  
Change medium into pre-equilibrated Optimised Growth Medium (+/- control/test compounds)  
as required  
Incubate

### 5.3. Day 4

Examine cultures microscopically  
Change medium into pre-equilibrated Optimised Growth medium (+/- control or test  
compounds)

### 5.4. Day 6

Repeat **Day 4** procedure

### 5.5. Day 8

Repeat **Day 4** procedure

### 5.6. Day 10

Repeat **Day 4** procedure

### 5.7. Day 12

Repeat **Day 4** procedure

### 5.8. Day 14

Examine cultures microscopically  
Fix cells and stain tubules  
Score results either manually, colorimetrically or using the TCS Cellworks AngioSys image  
analysis software.

\* To determine effects of test compounds on vasculogenesis, add test compounds on day 2.  
Alternatively, test compounds may be added at later time points to determine effects on  
angiogenesis.

## 6. Guidelines for Test Material Preparation

### 6.1. Test Compounds

Dissolve the compounds to be tested directly into Optimised Growth Medium supplied whenever possible.

If necessary, compounds may be dissolved in other solvents such as DMSO or ethanol. In this case a concentrated stock solution should be prepared and diluted with medium to give the required concentration of test compound. Final solvent concentrations should be kept constant and the experimental design should include control wells treated with solvent alone.

Final concentration of solvent should not exceed 0.1% (v/v) for DMSO and 0.1% (v/v) for ethanol. **N.B.** Ethanol is known to have an angiogenic effect at 1-5% (v/v)<sup>14</sup>.

### 6.2. Explants

Ensure sterility of tissue explants has been maintained prior to their addition to cultures.

Small explants of approximately 2-3mm<sup>2</sup> should be placed in a well at the Day 2 or Day 4 medium change. The plate should then not be disturbed until the next medium change.

Medium aspiration and replacement must be performed with care to ensure that the explant is not dislodged or the cell sheet damaged. Exact protocols must be determined by each researcher as required.

### 6.3. Conditioned Media

Conditioned medium from other cell cultures may be diluted in fresh Optimised Growth Medium supplied with this kit and added directly to the plate. It is recommended that conditioned medium should be diluted at least 1:1 in fresh medium. This guideline must be verified by experiments for each conditioned medium tested.

## 7. General Tips

Ensure all components that require storage are maintained at the correct temperature, see section 3 for storage conditions. Check kit and component expiry dates before use.

Prepare your tissue culture laminar flow hood and all necessary equipment prior to starting the assay.

Pre-equilibrate medium before adding to cultures. Equilibration with respect to CO<sub>2</sub> is as important as temperature equilibration.

Have required dilutions of test compound(s) in medium prepared ready for use before starting medium changes.

## 8. V2a Protocol

***Use rigorous aseptic technique at all times. Only open the culture plate and medium bottles in a sterile laminar flow hood.***

### 8.1. Day 1

- 8.1.1. Thaw Seeding Medium Supplement and add to the 25ml bottle of Optimised Seeding Medium. Mix well.
- 8.1.2. Add 0.5ml Optimised Seeding Medium to each well of the 24 well plate. Incubate the plate at 37°C with 5% CO<sub>2</sub> in a humidified environment for 30 minutes to pre-equilibrate.
- 8.1.3. Accurately pipette 12ml Optimised Seeding Medium into a universal container. Rapidly thaw the ampoule of cryopreserved cells in a 37°C water bath until just a few ice crystals are remaining. Wipe the outside of the vial with 70% ethanol or isopropanol.
- 8.1.4. Aseptically open the ampoule and add all the cells to the 12ml Optimised Seeding Medium.
- 8.1.5. Mix cells and Optimised Seeding Medium with a serological pipette before adding 0.5ml of cell suspension to each well of the 24 well plate to give a final well volume of 1ml per well. Ensure that the cell mixture remains evenly mixed during this process.
- 8.1.6. After addition of cell suspension to all wells make sure that the cells are evenly dispersed in the wells. **This is important to avoid cell clumping and subsequent over confluence in part of a well.**
- 8.1.7. Place the 24 well plate in an incubator at 37°C with 5% CO<sub>2</sub> humidified atmosphere.

### 8.2. Day 2

- 8.2.1. Thaw Growth Medium Supplement and add it to 125ml Optimised Growth Medium.
- 8.2.2. Mix well and pre-equilibrate the Optimised Growth Medium by opening lid 1/4 of a turn and placing in an incubator for 30 minutes at 37°C with 5% CO<sub>2</sub> humidified atmosphere.
- 8.2.3. Prepare dilutions of control components as follows:
  - Thaw VEGF positive control solution and add 10µl to 10ml pre-equilibrated Optimised Growth Medium
  - Thaw Suramin negative control and add 200µl to 10ml pre-equilibrated Optimised Growth Medium

There is sufficient volume of control solutions to be used at each medium change during the assay. Store solutions at 2-8°C when not in use; always pre-equilibrate before use.

- 8.2.4. Prepare dilutions of test compounds in pre-equilibrated Optimised Growth Medium and mix well (see section 6).
- 8.2.5. Remove 24 well plate from the incubator and examine cultures microscopically for cell morphology and signs of growth.
- 8.2.6. Carefully aspirate medium from wells without touching the cell layer. Make sure that no droplets are left around the well walls. **To avoid possible desiccation of cells, we recommend replacing medium 4 wells at a time rather than aspirating medium from all 24 wells in a single operation.**
- 8.2.7. Using a serological pipette, gently, down the side of the well, add 0.5ml pre-equilibrated Optimised Growth Medium containing test or control materials as required per well (see example plate layout in section 8.5). **Do not use micropipettes (e.g. Gilson pipettes) as they will cause damage to the culture. Do not attempt to mix test compounds directly in the culture plate as this will also damage the cell monolayer.**
- 8.2.8. Incubate the plate at 37°C with 5% CO<sub>2</sub> humidified atmosphere.

### **8.3. Days 4, 6, 8, 10 and 12\***

- 8.3.1. Pre-equilibrate Optimised Growth Medium, VEGF control, Suramin controls and any test compounds according to section 8.2.2.
- 8.3.2. Prepare dilutions of test compounds as described in the day 2 procedure if required (section 8.2.4.).
- 8.3.3. Carefully examine cultures microscopically for cell morphology and signs of growth. Proceed when you are satisfied that cultures appear normal.
- 8.3.4. Aspirate and replace media with Optimised Growth Media containing control or test compounds as required, according to the day 2 procedure (section 8.2.6. and 8.2.7.).
- 8.3.5. Incubate the plate at 37°C with 5% CO<sub>2</sub> humidified atmosphere.


**\*Although we recommend media changes every 2 days, it is usually possible to leave cultures over a weekend and change media after 3 days without any adverse effect on the cells. This only applies to cultures from the end of Day 2 onwards. Each user must verify this in their own laboratory.**

## 8.4. Day 14

8.4.1. After examining the cultures to monitor tubule development, fix them prior to visualisation. See Section 9 for detailed protocols.

The formation of tubules can be monitored by light microscopy. Tubule lumens are visible if phase contrast microscopy is utilised. The extent of tubule formation however, can be difficult to judge in unstained plates and requires a reasonable level of experience.

## 8.5. Example Plate Layout



VEGF: Positive control  
Media only: Untreated control well.  
Suramin: Negative control

## 9. Fixing and Staining Protocols

***Wear gloves throughout the fixing and staining procedures.***

Visualisation of tubules is more difficult in cultures that are not stained. To facilitate analysis it is best to fix the cells at the end of the experiment and stain for one or more endothelial markers. This is essential if image analysis software is to be used for tubule quantification, for example TCS Cellworks AngioSys. A fully functional 30 day use demonstration version of this software is available free of charge (conditions apply, please contact TCS Cellworks).

Recommended markers are CD31 (PECAM-1) or von Willebrand Factor.

The **V2a Kit** contains all the reagents necessary to complete both the CD31 ELISA assay staining procedure using a soluble colour substrate (p-NPP) followed by the permanent CD31 staining (BCIP/NBT) for image analysis and/or archiving of the plate.

### 9.1. Culture Fixation Protocol

Prepare the necessary reagents as described below:

#### 9.1.1. Wash Buffer (Dulbecco's Phosphate-Buffered Saline)

Per litre:	KCl	0.20g
	KH <sub>2</sub> PO <sub>4</sub>	0.20g
	NaCl	8.00g
	Na <sub>2</sub> HPO <sub>4</sub>	1.15g

Store at 4°C. Pre-equilibrate to room temperature before use.

#### 9.1.2. Blocking Buffer

Prepare 150ml of Wash Buffer (see section 9.1.1.) and supplement with 1% BSA.  
Store at 4°C. Pre-equilibrate to room temperature before use.

#### 9.1.3. Fixative

70% ethanol.  
Store at -20°C. Use immediately from freezer.

#### 9.1.4. Fixation Protocol

9.1.4.1. Aspirate medium from cells very carefully.

9.1.4.1. Wash each well with 0.5ml Washing Buffer. Take care not to disturb the cell sheet in the well when removing the buffer.

- 9.1.4.2. Add 0.5ml of ice cold fixative carefully to each well.
- 9.1.4.3. Incubate at room temperature for 30 minutes.
- 9.1.4.4. Decant the fixative and wash wells 3 times with 0.5ml Blocking Buffer.
- 9.1.4.5. Decant final wash and add primary staining antibody as detailed below.

***Do not allow the cell sheet to dry out until staining has been completed.***

## **9.2. Staining for CD31 (PECAM-1)**

***Only proceed with staining after cultures have been fixed as described above. Centrifuge vials of antibody before opening.***

All the CD31 staining kits available from TCS Cellworks use identical primary and secondary antibody treatments as detailed below. Different chromogenic substrates are used however, for the ELISA assay (soluble p-NPP) or for tubule staining *in situ* (insoluble BCIP/NBT).

### **9.2.1. Anti-CD31 primary and anti-IgG Alkaline Phosphatase secondary antibody treatments**

- 9.2.1.1. Dilute primary antibody (mouse anti-human CD31) 1:400 in Blocking Buffer (35µl antibody in 14ml Blocking Buffer), mix well.
- 9.2.1.2. Add 0.5ml diluted primary antibody per well, incubate for 60 minutes at 37°C.
- 9.2.1.3. Immediately prior to washing off the primary antibody, prepare the secondary antibody (goat anti-mouse IgG AP conjugate). Dilute the secondary antibody 1:500 in Blocking Buffer (28µl in 14ml Blocking Buffer), mix well.
- 9.2.1.4. Remove the primary antibody solution.
- 9.2.1.5. Wash each well with 0.5ml Blocking Buffer and incubate each wash at room temperature for 5 minutes. Decant.
- 9.2.1.6. Repeat the wash step 9.2.1.5. two more times. Decant final wash prior to adding secondary antibody.
- 9.2.1.7. Add 0.5 ml diluted secondary antibody conjugate per well. Incubate for 60 minutes at 37°C.
- 9.2.1.8. Wash wells three times with 0.5ml dH<sub>2</sub>O, following the procedure for washing off the primary antibody.

***To perform the optional ELISA stain, proceed to section 9.2.2 otherwise proceed immediately to section 9.2.3 to permanently stain tubules for image analysis and plate archiving.***

### **9.2.2. CD31 ELISA Soluble Substrate (p-NPP) – optional**

- 9.2.2.1. Prepare soluble substrate by dissolving one p-Nitrophenol phosphate (p-NPP) tablet (silver) and one Tris buffer tablet (gold) in 20ml dH<sub>2</sub>O. Use within 1 hour.
- 9.2.2.2. Prepare 96 well plate by adding 25µl 3M NaOH to 50 wells.
- 9.2.2.3. Add 100µl p-NPP substrate directly to 2 of these wells (blanks).
- 9.2.2.4. Add 0.3ml p-NPP to each of the **V2a Kit** 24 wells, incubate at 37°C for exactly 20 minutes.
- 9.2.2.5. Remove two 100µl aliquots from the first well of the **V2a Kit** and add each to separate wells of the 96 well plate already containing 3M NaOH.
- 9.2.2.6. Repeat for each **V2a Kit** well. You will have 48 test wells plus 2 p-NPP blank control wells on the 96 well plate.
- 9.2.2.7. Read the 96 well plate at 405nm against the blank wells.
- 9.2.2.8. Wash the **V2a Kit** wells carefully 3 times with 0.5ml dH<sub>2</sub>O. Discard the final wash and continue with tubule staining procedure (section 9.2.3).

***Proceed immediately with the insoluble staining procedure below to enable automated scoring and provide a permanent record of tubule development. Do not allow the cell sheet to dry out until the staining has been completed.***

### **9.2.3. CD31 Tubule Staining Insoluble Substrate (BCIP/NBT)**

- 9.2.3.1. Prepare insoluble (BCIP/NBT) substrate immediately prior to addition to the **V2a Kit**: dissolve two BCIP/NBT tablets in 20ml dH<sub>2</sub>O.
- 9.2.3.2. Filter substrate using disposable syringe and 0.2µm filter disc. Use within 1 hour.
- 9.2.3.3. Add 0.5ml substrate to each **V2a Kit** well, incubate at room temperature until tubules develop a dark purple colour (usually 3-10 minutes). Staining should be continually monitored and should not exceed 20 minutes.
- 9.2.3.4. Wash wells carefully three times with 0.5ml dH<sub>2</sub>O. Discard final wash and leave to air dry.

Plates can be stored in the dark indefinitely but colour intensity will fade with time. For best results, plates should be photographed or an image recorded as soon as possible after staining.

## 10. Scoring Results

### 10.1. Optical Density Measurement (ELISA)

*For scoring plates stained per sections 9.2.1. and 9.2.2.*

This provides a rapid overview of the extent of tubule development which may be sufficient for comparative evaluation of different angiogenic effector concentrations. It cannot however, provide the detailed information on tubule morphology etc that is available when the tubules are stained using histochemical techniques.

### 10.2. Tubule Quantification and Analysis Following Histochemical Staining

*For scoring plates stained per sections 9.2.1. and 9.2.3.*

Tubule formation can be scored either manually or with the aid of TCS Cellworks **AngioSys Image Analysis Software**. The full extent of tubule development can be difficult to assess in unstained cultures. It is essential that cultures are fixed and stained prior to definitive scoring.

#### 10.2.1. Manual Scoring

##### 10.2.1.1. By eye

It is possible to estimate the extent of tubule formation by eye, for example using a plus scale to designate tubule density. It is recommended that the maximum area practically possible should be examined in each well (this will probably depend on the optical set up in use). Scoring by eye in this way can only provide semi-quantitative, comparative results.

##### 10.2.1.2. Chalkley graticule

Another means of manually measuring the tubules uses a 25-point Chalkley point eyepiece graticule ( see Fox, S.B., *et al*, 1995 J Pathol. **177** 275-283). Microvessel density is assessed in a chosen area, following low power scanning. This method does not require storing of images and analysis takes approximately 3 minutes per field assessed.

##### 10.2.1.3. By map reader

The total length of tubules can be determined accurately by tracing photographs using a map reading distance wheel. As above, multiple fields, covering the maximum area practically possible for each well, should be photographed to maximise precision of the measurements taken.

### 10.2.2. Automated Scoring with AngioSys

A dedicated software package, TCS Cellworks **AngioSys Image Analysis Software** (product code ZHA-1800) has been developed for quantitative measurement of tubule development in the **V2a Kit** and is available to purchase. This permits analysis of total tubule number, total tubule length, mean tubule length and number of junctions, or other parameters required by the investigator. A 30 day use demonstration version can be supplied free of charge to score the Angiogenesis assay\*.

\* Conditions apply; please contact TCS Cellworks for further details.

Other image analysis software may be adapted to score the Angiogenesis assay. In this case, it is advised that CD31 (PECAM-1) with BCIP/NBT substrate (ZHA-1225 kit) is used for staining as it gives better contrast.

## 11. Trouble Shooting

Symptom	Possible Reasons/Solutions
No tubule formation	<ul style="list-style-type: none"> <li>i. High concentrations of angiogenic inhibitors have prevented tubule formation. Check control wells.</li> <li>ii. Solvent used to dissolve test compounds may be at a toxic concentration. Run one or more solvent control wells.</li> <li>iii. Cultures have died. May be due to a number of reasons:               <ul style="list-style-type: none"> <li>a. Cells were allowed to become dry between medium changes. Aspirate old medium from only a few wells at a time and replace with fresh optimised medium before aspirating the next wells.</li> <li>b. Final concentration of solvent in which treatment is dissolved, is too high. Make a more concentrated stock solution of test compound and dilute this further in medium.</li> <li>c. Ensure all incubations are at 37°C in a 5% CO<sub>2</sub> humidified atmosphere.</li> </ul> </li> </ul>
Cell sheet detaching from the well surface	<ul style="list-style-type: none"> <li>i. Cultures have been left to grow for too long. Try to fix and stain cultures before this occurs. Contact TCS Cellworks if this occurs before Day 14. If the sheet is still partially attached to the well, attempt to gently fix and stain the tubules.</li> </ul>
Cells floating in well	<ul style="list-style-type: none"> <li>i. This is the result of adding fresh medium too fast. Always add fresh medium very gently to prevent dislodging cells. Never use micropipettes for adding medium.</li> <li>ii. Cultures have died. See above for possible reasons.</li> </ul>
Faint Staining of tubules	<ul style="list-style-type: none"> <li>i. Antibodies not added at the correct concentration. See section 9.</li> <li>ii. Antibody incubation was too short or was performed at the incorrect temperature. See section 9.</li> <li>iii. Cultures left to grow for too long. The matrix is preventing adequate penetration of the primary antibody.</li> </ul>
A small number of wells are contaminated	<ul style="list-style-type: none"> <li>i. Act <b>promptly</b> to contain the contamination. Use your preferred method to achieve this. One possible method to use is given in Appendix I.</li> </ul>

## 12. Angiogenesis Related Products

<b>AngioKit – Human Angiogenesis Assay</b> This kit is an <i>in-vitro</i> human angiogenesis model supplied as a pre-seeded 24 well plate with co-culture cells. Untreated control wells form extensive tubule networks over a period of 6-11 days and allow for the testing of pro and anti-angiogenic compounds.	<b>ZHA-1000</b>
<b>Angiogenesis Control Reagent Kit</b> (contains VEGF and Suramin)	<b>ZHA-1300</b>
<b>Angiogenesis Tubule Staining Kit ELISA</b> (contains Anti-CD31, secondary antibody and soluble substrate only)	<b>ZHA-1100</b>
<b>Angiogenesis Tubule Staining Kit CD31</b> (contains Anti-CD31, secondary antibody and insoluble substrate)	<b>ZHA-1225</b>
<b>Angiogenesis Tubule Staining Kit ELISA and CD31</b> (contains Anti-CD31, secondary antibody with both soluble and insoluble substrate)	<b>ZHA-1125</b>
<b>Angiogenesis Tubule Staining Kit vWF</b> (contains Anti-von Willebrand Factor, secondary antibody and substrate)	<b>ZHA-1250</b>
<b>Angiogenesis Tubule Staining Kit CD31 and vWF</b> (contains Anti-CD31, Anti-von Willebrand Factor secondary antibodies and substrates)	<b>ZHA-1200</b>
<b>Optimised Growth Medium (100ml)</b>	<b>ZHA-1400</b>
<b>Anti-von Willebrand Factor polyclonal*</b>	
<b>Anti-PECAM-1 (CD31) monoclonal*</b>	
<b>Goat anti-mouse IgG; AP conjugate*</b> (Secondary for ZIS-3090)	
<b>Donkey anti-sheep IgG; HRP conjugate*</b> (Secondary for ZIS-9906)	
<b>AngioSys Image Analysis software full license</b> A free 30 day use demonstration disc is available - conditions apply.	<b>ZHA-1800</b>

\* Bulk preparations of antibodies used in the various staining kits. Please contact TCS Cellworks for ordering information.

## 13. References

### 13.1. General Angiogenesis References

1. Klagsbrun, M. & D'Amore, P.A. (1991) *Ann. Rev. Physiol.* **53**;217
2. Findlay, J.K. (1986) *J. Endocrinol.* **111**; 357
3. Folkman, J. (1972) *Ann. Surg.* **175**; 409
4. Davis, M.D. (1988) *Diabetes/Metab. Rev.* **4**; 291
5. Folkman, J. (1985) *Adv. Cancer Res.* **43**; 175
6. Folkman, J. & Klagsbrun, M. (1987) *Science* **235**; 442
7. Ausprunk, D.H. & Folkman, J. (1977) *Microvasc. Res.* **14**; 53
8. Sholley, M.M. *et al* (1984) *Lab. Invest.* **51**; 624
9. Vu *et al* (1985) *Lab. Invest.* **53**; 499
10. Gimbrone, M.A. *et al* (1972) *J. Exp. Med.* **136**; 261
11. Connolly, D.T. *et al* (1989) *J. Clin. Invest.* **84**; 1470
12. Rupnick, M.A. *et al* (1988) *Lab. Invest.* **59**; 363
13. Passaniti, A. *et al* (1992) *Lab. Invest.* **67**; 519
14. Jones *et al* (1998) *Biochem Biophys Res Commun* **249(1)**, 118

### 13.2. Selected Publications Citing TCS Cellworks AngioKit

15. Secchiero, P. *et al*, 2007. *Circulation Research*, **100**, 61-69
16. Cudmore, M. *et al*, 2006. *Biochemical and Biophysical Research Communications*, **345(4)**, pp.1275-1282
17. Bozaoglu, K. *et al*, 2010. *Journal of Clinical Endocrinology and Metabolism*, **95(5)**, pp.2476-2485
18. Baker, N. *et al*, 2009. *Journal of Immunology*, **182**, pp.3819-3826
19. Wang, B. *et al*, 2010. *Microvascular Research*, **80(1)**, pp.31-36
20. Hose, D. *et al*, 2009. *Blood*, **114(1)**, pp.128-143
21. Boehme, V. *et al*, 2009. *Blood*, **114(2)**, pp.380-393
22. Seckinger, A. *et al*, 2009. *Oncogene*, **28**, pp.3866-3879
23. Ramakrishnan, V. *et al*, 2009. *Oncogene*, **29**, pp.1190-1202
24. Brcic, L. *et al*, 2009. *Journal of Physiology and Pharmacology*, **60(7)**, pp.191-196
25. Sordi, V. *et al*, 2010. *Stem Cells*, **28(1)**, pp.140-151
26. Pellizzaro, C. *et al*, 2008. *Pancreas*, **36(4)**, pp.e15-e23
27. Wilson, C. *et al*, 2008. *British Journal of Cancer*, **99**, pp.2054-2064
28. Kane, R. *et al*, 2008. *Molecular Vision*, **14**, pp.1138-1148
29. Simcock, D.E. *et al*, 2008. *American Journal of Respiratory and Critical Care Medicine*, **177**, pp.460-468
30. Leu, A. *et al*, 2008. *Pharmaceutical Research*, **25(5)**, pp.1222-1229
31. Malik, M.K. *et al*, 2010. *Rheumatology Advance Access*, 0, pp.keq163vl-keq163
32. Chen, Y. *et al*, 2008. *BMC Genomics*, **9(264)**
33. Akhavan, M.A. *et al*, 2009. *Arthritis Research and Therapy*, **11(R64)**
34. Luistro, L. *et al*, 2009. *Cancer Research*, **9**, pp.1618-1628
35. Yang, J. *et al*, 2010. *Clinical Lymphoma, Myeloma and Leukemia*, **9(1)**, pp.S96-S168

## 14. Technical Assistance

For technical assistance please contact:

**TCS Cellworks Ltd,**  
Whiteleaf Business Centre,  
11 Little Balmer,  
Buckingham,  
MK18 1TF.

Tel: 01280 827475  
Fax: 01280 827477  
E-mail: [office@tcscellworks.co.uk](mailto:office@tcscellworks.co.uk)  
Website: [www.tcscellworks.co.uk](http://www.tcscellworks.co.uk)

## Appendix I

### *Suggested protocol for containing contamination*

- Fill the infected wells using 1M NaOH. Take care to avoid any spillage into adjacent wells.
- Leave for 2-3 hours.
- Aspirate well taking great care not to cause any aerosols.
- Leave the well empty for the duration of the experiment.

**[Blank Page]**

**[Blank Page]**



### Intellectual Property Protection

**Note that the V2a Kit is protected by US patent 6225118, GB patent 2331763 and European patent 1023599.  
Other patents are pending.**



**Tel:** +44 (0)1280 827475

**Fax:** +44 (0)1280 827477

**E-mail:** [office@tcscellworks.co.uk](mailto:office@tcscellworks.co.uk)

**Web:** [www.tcscellworks.co.uk](http://www.tcscellworks.co.uk)

**Address:** TCS Cellworks Ltd, Whiteleaf Business Centre, 11 Little Balmer, Buckingham, MK18 1TF,